FDA’s On­col­o­gy Cen­ter of Ex­cel­lence touts 2018 ac­com­plish­ments

Im­age: Richard Paz­dur. FDA via FLICKR

The FDA’s re­cent­ly cre­at­ed in­ter-cen­ter On­col­o­gy Cen­ter of Ex­cel­lence (OCE) on Mon­day re­leased its first-ever an­nu­al re­port tout­ing its ac­com­plish­ments in 2018.

OCE was launched in 2017 to speed the de­vel­op­ment and re­view of on­col­o­gy prod­ucts across the FDA’s three med­ical prod­uct cen­ters.

“In 2018, we es­tab­lished a core OCE man­age­ment team and con­tin­ued the work be­gun in 2017 of build­ing pro­grams and launch­ing ini­tia­tives to lever­age ex­per­tise across the FDA and oth­er fed­er­al health agen­cies, as well as acad­e­mia, com­mu­ni­ty prac­ti­tion­ers, and in­dus­try, to ad­vance the de­vel­op­ment and reg­u­la­tion of prod­ucts for peo­ple with can­cer,” writes OCE Di­rec­tor Richard Paz­dur.

2018

With its goal of ex­pe­dit­ing the de­vel­op­ment and re­view of on­col­o­gy and hema­tol­ogy prod­ucts, OCE high­lights the num­ber of reg­u­la­to­ry de­ci­sions it made for new and ex­ist­ing prod­ucts in 2018.

These de­ci­sions in­clude the ap­proval of 19 new mol­e­c­u­lar en­ti­ties (NMEs) and orig­i­nal bi­o­log­ics li­cense ap­pli­ca­tions (BLAs), two biosim­i­lars and a pre­mar­ket ap­proval (PMA) for a new com­pan­ion di­ag­nos­tic that tests for a ge­net­ic mu­ta­tion in pa­tients with acute myeloid leukemia.

2018 On­col­o­gy Ap­provals
19 New Mol­e­c­u­lar En­ti­ties (NMEs)/Bi­o­log­ics Li­cense Ap­pli­ca­tions (BLAs) 32 Ef­fi­ca­cy Sup­ple­ments (New In­di­ca­tions) 1 Ef­fi­ca­cy Sup­ple­ment (New Pa­tient Pop­u­la­tion)
2 Ef­fi­ca­cy Sup­ple­ments (Ac­cel­er­at­ed Ap­proval Con­fir­ma­to­ry Study) 2 Biosim­i­lars 9 505(b)(2) Ap­provals
1 Pre­mar­ket Ap­proval (PMA) – (New Com­pan­ion Di­ag­nos­tic) 10 PMAs (Mod­i­fi­ca­tion to Com­pan­ion Di­ag­nos­tic) 1 PMA (Com­bi­na­tion Prod­uct

The re­port points out that 10 of these ap­provals lever­aged one or both of the cen­ter’s pi­lot re­view pro­grams, re­al time on­col­o­gy re­view (RTOR) and as­sess­ment aid (AAid).

The OCE al­so took part in re­view­ing more than 140 ap­pli­ca­tions for the FDA’s ex­pe­dit­ed pro­grams, in­clud­ing fast track, break­through ther­a­py des­ig­na­tion (BTD), re­gen­er­a­tive med­i­cine ad­vanced ther­a­py (RMAT) and break­through de­vice des­ig­na­tion.

OCE 2018 Ex­pe­dit­ed Pro­gram Sub­mis­sions
Ex­pe­dit­ed Pro­gram Grant­ed De­nied With­drawn
Fast Track 35 22 N/A
Break­through Ther­a­py 25 16 10
Re­gen­er­a­tive Med­i­cine Ad­vanced Ther­a­py 2 4 0
Break­through De­vice Des­ig­na­tion 18 5 4

In 2018, OCE helped de­vel­op 10 guid­ance and one fi­nal guid­ance doc­u­ments cov­er­ing a range of is­sues from clin­i­cal tri­al end­points for can­cer drugs to de­vel­op­ing and la­bel­ing com­pan­ion di­ag­nos­tics for spe­cif­ic on­col­o­gy ther­a­pies. OCE al­so con­vened 18 pub­lic work­shops and 16 ed­u­ca­tion­al sym­posia in 2018.

In­ter­na­tion­al Col­lab­o­ra­tion

Ke Liu

On the in­ter­na­tion­al front, Paz­dur along with OCE Act­ing As­so­ci­ate Di­rec­tor for Cell and Gene Ther­a­py Ke Liu and Act­ing As­sis­tant Com­mis­sion­er for In­ter­na­tion­al Pro­grams Leigh Ver­bois met with reg­u­la­tors, aca­d­e­mics and in­dus­try in Chi­na in Ju­ly 2018.

Leigh Ver­bois

“Dur­ing our vis­its to Bei­jing, Zhengzhou, Suzhou, and Shang­hai, we de­scribed FDA’s ini­tia­tives in ex­pe­dit­ing the de­vel­op­ment of on­col­o­gy prod­ucts, con­veyed the FDA’s ex­pe­ri­ence in ac­cel­er­at­ing the process of bring­ing in­no­v­a­tive ther­a­pies to mar­ket while main­tain­ing high stan­dards of safe­ty and ef­fi­ca­cy,” the re­port states.

OCE al­so holds month­ly on­col­o­gy in­ter­na­tion­al clus­ter meet­ings with its coun­ter­parts at the Eu­ro­pean Med­i­cines Agency, Health Cana­da, Japan’s Phar­ma­ceu­ti­cals and Med­ical De­vices Agency, Switzer­land’s Swissmedic and Aus­tralia’s Ther­a­peu­tic Goods Ad­min­is­tra­tion.


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Overview
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Roger Perlmutter, Merck

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months after making a splash at the European Hematology Association scientific confab with an early snapshot of positive data for their BTK inhibitor ARQ 531, ArQule has won a $2.7 billion buyout deal from Merck.

Merck is scooping up a next-gen BTK drug — which is making a splash at ASH today — from ArQule in an M&A pact set at $20 a share $ARQL. That’s more than twice Friday’s $9.66 close. And Merck R&D chief Roger Perlmutter heralded a deal that nets “multiple clinical-stage oral kinase inhibitors.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.

Game on: Re­gen­eron's BC­MA bis­pe­cif­ic makes clin­i­cal da­ta de­but, kick­ing off mul­ti­ple myelo­ma matchup with Bris­tol-My­ers

As J&J attempts to jostle past Bristol-Myers Squibb and bluebird for a landmark approval of its anti-BCMA CAR-T — and while GlaxoSmithKline maps a quick path to the FDA riding on its own BCMA-targeting antibody-drug conjugates — the bispecifics are arriving on the scene to stake a claim for a market that could cross $10 billion per year.

The main rivalry in multiple myeloma is shaping up to be one between Regeneron and Bristol-Myers, which picked up a bispecific antibody to BCMA through its recently closed $74 billion takeover of Celgene. Both presented promising first-in-human data at the ASH 2019 meeting.

FDA lifts hold on Abeon­a's but­ter­fly dis­ease ther­a­py, paving way for piv­otal study

It’s been a difficult few years for gene and cell therapy startup Abeona Therapeutics. Its newly crowned chief Carsten Thiel was forced out last year following accusations of unspecified “personal misconduct,” and this September, the FDA imposed a clinical hold on its therapy for a form of “butterfly” disease. But things are beginning to perk up. On Monday, the company said the regulator had lifted its hold and the experimental therapy is now set to be evaluated in a late-stage study.

Paul Hudson. Sanofi

New Sanofi CEO Hud­son adds next-gen can­cer drug tech to the R&D quest, buy­ing Syn­thorx for $2.5B

When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about.

The French pharma giant announced early Monday that it is snagging San Diego biotech Synthorx in a $2.5 billion deal. That marks an affordable bolt-on for Sanofi but a considerable return for Synthorx backers, including Avalon, RA Capital and OrbiMed: At $68 per share, the price represents a 172% premium to Friday’s closing.

Synthorx’s take on alternative IL-2 drugs for both cancer and autoimmune disorders — enabled by a synthetic DNA base pair pioneered by Scripps professor Floyd Romesberg — “fits perfectly” with the kind of innovation that he wants at Sanofi, Hudson said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.

Roche faces an­oth­er de­lay in strug­gle to nav­i­gate Spark deal past reg­u­la­tors — but this one is very short

Roche today issued the latest in a long string of delays of its $4.3 billion buyout of Philadelphia-based Spark Therapeutics. The delay comes as little surprise — it is their 10th in as many months — as their most recent delay was scheduled to expire before a key regulatory deadline.

But it is notable for its length: 6 days.

Previous extensions had moved the goalposts by about 3 weeks to a month, with the latest on November 22 expiring tomorrow. The new delay sets a deadline for next Monday, December 16, the same day by which the UK Competition and Markets Authority has to give its initial ruling on the deal. And they already reportedly have lined up an OK from the FTC staff – although that’s only one level of a multi-step process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.

KalVis­ta's di­a­bet­ic mac­u­lar ede­ma da­ta falls short — will Mer­ck walk away?

Merck’s 2017 bet on KalVista Pharmaceuticals may have soured, after the UK/US-based biotech’s lead drug failed a mid-stage study in patients with diabetic macular edema (DME).

Two doses of the intravitreal injection, KVD001, were tested against a placebo in a 129-patient trial. Patients who continued to experience significant inflammation and diminished visual acuity, despite anti-VEGF therapy, were recruited to the trial. Typically patients with DME — the most frequent cause of vision loss related to diabetes — are treated with anti-VEGF therapies such as Regeneron’s flagship Eylea or Roche’s Avastin and Lucentis.

UP­DAT­ED: Ob­sE­va makes case for best-in-class hor­mone sup­pres­sive ther­a­py in pos­i­tive uter­ine fi­broid study

About a month after the Swiss biotech disclosed a failed late-stage study in its IVF program, ObsEva on Monday unveiled positive pivotal data on its experimental treatment for heavy menstrual bleeding triggered by uterine fibroids.

ObsEva in-licensed the drug, linzagolix, from Japan’s Kissei Pharmaceutical in 2015. Two doses of the drug (100 mg and 200 mg) were tested against a placebo in the 535-patient Phase III study, dubbed PRIMROSE 2, in patients who were both on and off hormonal add-back therapy (ABT).

Ear­ly-stage can­cer biotech nails $85M C round; Flem­ming Orn­skov's Gal­der­ma scores 'break­through' sta­tus

→ Zentalis Pharmaceuticals just nabbed an $85 million round from a syndicate that includes Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Surveyor Capital and Eventide Asset Management. Their lead drug is ZN-c5, which is currently in Phase I/II trials. The biotech describes that drug as a “potential best-in-class oral Selective Estrogen Receptor Degrader for estrogen receptor-positive, HER2-negative (ER+/ HER2-) breast cancer.”